Trial
NCT03979508
Abemaciclib in Treating Patients With Surgically Resectable, Chemotherapy Resistant, Triple Negative Breast Cancer
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Mayo Clinic
Collaborators
—
Condition
Anatomic Stage I Breast Cancer AJCC v8
Intervention
Abemaciclib
Why stopped
The primary biomarker (CD8/FOXP3) was rarely observed to be \< 1.6 in residual tumors examined in first stage of study.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-11-12